Novo Nordisk A/S logo
Novo Nordisk A/S (NVO)
Compare

Novo Nordisk A/S (NVO) Earnings Per Share (EPS): 4.27

popular:market cap|pe ratio|revenue|price history|total return

Is Novo Nordisk A/S’s earnings per share (EPS) high or low?

Novo Nordisk A/S's earnings per share (EPS) of 4.27 is 79% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–4.27).

As of Wednesday, June 17, 2026. 26.41% above its 12-month average of 3.38.

P/E Ratio|EPS CAGR|Net Income|Earnings Yield|All Metrics

NVO Earnings Per Share (EPS) Chart

NVO Earnings Per Share (EPS)
3.62+15.32% 1Y
Zoom

NVO Average Earnings Per Share (EPS) Chart

NVO Current vs Average Earnings Per Share (EPS) Chart

NVO Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

4.27

EARNINGS PER SHARE (EPS) AVG TTM

3.38

EARNINGS PER SHARE (EPS) AVG 3Y

2.82

EARNINGS PER SHARE (EPS) AVG 5Y

2.39

EARNINGS PER SHARE (EPS) AVG 10Y

1.83

EARNINGS PER SHARE (EPS) AVG 15Y

1.19

EARNINGS PER SHARE (EPS) AVG 20Y

0.94

CURRENT VS TTM AVG

+26.41%

CURRENT VS 3Y AVG

+51.44%

CURRENT VS 5Y AVG

+78.57%

CURRENT VS 10Y AVG

+133.80%

CURRENT VS 15Y AVG

+258.40%

CURRENT VS 20Y AVG

+353.28%

NVO Competitors' Earnings Per Share (EPS)

NAMEMARKET CAPEARNINGS PER SHARE (EPS)TTM3Y5Y
Novo Nordisk A/S (NVO)$193.39B4.273.382.822.39
Amgen Inc. (AMGN)vs ›$184.40B14.3710.9711.6711.57
Thermo Fisher Scientific Inc. (TMO)vs ›$171.57B18.1917.1716.9017.22
Gilead Sciences, Inc. (GILD)vs ›$155.75B7.343.613.853.41
Abbott Laboratories (ABT)vs ›$154.08B3.595.714.664.19
Pfizer Inc. (PFE)vs ›$147.73B1.311.392.192.39
Intuitive Surgical, Inc. (ISRG)vs ›$142.44B8.257.275.845.20
Danaher Corporation (DHR)vs ›$128.06B5.175.206.666.73
CVS Health Corporation (CVS)vs ›$127.73B2.272.533.714.39
Vertex Pharmaceuticals Incorporated (VRTX)vs ›$116.49B16.866.6910.109.99

EPS Comparison

Trailing EPS (TTM)

$4.27

Forward EPS (Est.)

$21.64

P/E Ratio

10.2

Formula: EPS = Net Income / Weighted Average Shares Outstanding

Why EPS matters:

  • Directly impacts stock valuation through P/E ratio
  • Used to calculate dividend coverage and payout ratios
  • Enables comparison across companies of different sizes
  • Growth in EPS often correlates with stock price appreciation

Novo Nordisk A/S Earnings Per Share (EPS) Formula & Definition

EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Novo Nordisk A/S Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The earnings per share (EPS) for NVO stock is 4.27.
Is Novo Nordisk A/S's earnings per share (EPS) high or low?
Novo Nordisk A/S's earnings per share (EPS) of 4.27 is 79% above its 5-year average of 2.39, near the high end of its 5-year range (1.48–4.27).
What is the TTM average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The TTM average earnings per share (EPS) for NVO stock is 3.38.
What is the 3Y average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The 3Y average earnings per share (EPS) for NVO stock is 2.82.
What is the 5Y average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The 5Y average earnings per share (EPS) for NVO stock is 2.39.
What is the 10Y average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The 10Y average earnings per share (EPS) for NVO stock is 1.83.
What is the 15Y average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The 15Y average earnings per share (EPS) for NVO stock is 1.19.
What is the 20Y average earnings per share (EPS) for Novo Nordisk A/S (NVO)?
The 20Y average earnings per share (EPS) for NVO stock is 0.94.

Novo Nordisk A/S Earnings Per Share (EPS) History

DATEEARNINGS PER SHARE (EPS)
2025-12-313.62
2024-12-313.14
2023-12-312.76
2022-12-311.76
2021-12-311.59
2020-12-311.48
2019-12-311.23
2018-12-311.23
2017-12-311.24
2016-12-311.06
2015-12-310.99
2014-12-310.82
2013-12-310.87
2012-12-310.69
2011-12-310.53
2010-12-310.44
2009-12-310.35
2008-12-310.29
2007-12-310.26
2006-12-310.18
2005-12-310.14
2004-12-310.14
2003-12-310.12
2002-12-310.09
2001-12-310.09
2000-12-310.07
1999-12-310.05
1998-12-310.05
1997-12-310.05
1996-12-310.04

Related Metrics

P/E RatioEPS CAGRNet IncomeEarnings YieldAll Metrics

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd
77,406 employees
www.novonordisk.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
View full financials